Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices

Behzad Soleimani, Annick Haouzi, Angela Manoskey, Edward Stephenson, Aly El-Banayosy, Walter Pae

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Development of aortic insufficiency (AI) in patients supported with continuous flow left ventricular assist devices (LVAD) can adversely affect pump performance. In this study, we examined the incidence of new AI after LVAD implant at our institution. Pre- and postoperative echocardiograms of 66 patients who received HeartMate II or Heartware LVAD at our institution since June 2008 were reviewed for presence of new AI. Median LVAD support duration was 221 days. New AI developed in 6 patients (9.5%) after a median time of 374.5 days of support. There were no cases of severe or symptomatic AI. There was no significant difference between the AI incidence between HeartMate II and Heartware recipients. For patients who remained on LVAD support at 6 and 12 months, freedom from AI was 100% and 68.4%, respectively. Age, destination therapy status, and duration of support were predictors of new AI after LVAD implant. In conclusion, AI develops frequently during long-term support with continuous flow LVADs, particularly in those supported for longer than 6 months. As we move to the era of long-term LVAD support and destination therapy, further studies with longer follow-ups are required to determine the progression and clinical significance of AI in these patients.

Original languageEnglish (US)
Pages (from-to)326-329
Number of pages4
JournalASAIO Journal
Volume58
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Incidence
Pumps
Therapeutics

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biophysics
  • Medicine(all)
  • Biomaterials
  • Biomedical Engineering

Cite this

@article{1398dbd1cd5c4b34a96f3ca5211a5c3c,
title = "Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices",
abstract = "Development of aortic insufficiency (AI) in patients supported with continuous flow left ventricular assist devices (LVAD) can adversely affect pump performance. In this study, we examined the incidence of new AI after LVAD implant at our institution. Pre- and postoperative echocardiograms of 66 patients who received HeartMate II or Heartware LVAD at our institution since June 2008 were reviewed for presence of new AI. Median LVAD support duration was 221 days. New AI developed in 6 patients (9.5{\%}) after a median time of 374.5 days of support. There were no cases of severe or symptomatic AI. There was no significant difference between the AI incidence between HeartMate II and Heartware recipients. For patients who remained on LVAD support at 6 and 12 months, freedom from AI was 100{\%} and 68.4{\%}, respectively. Age, destination therapy status, and duration of support were predictors of new AI after LVAD implant. In conclusion, AI develops frequently during long-term support with continuous flow LVADs, particularly in those supported for longer than 6 months. As we move to the era of long-term LVAD support and destination therapy, further studies with longer follow-ups are required to determine the progression and clinical significance of AI in these patients.",
author = "Behzad Soleimani and Annick Haouzi and Angela Manoskey and Edward Stephenson and Aly El-Banayosy and Walter Pae",
year = "2012",
month = "7",
day = "1",
doi = "10.1097/MAT.0b013e318251cfff",
language = "English (US)",
volume = "58",
pages = "326--329",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices. / Soleimani, Behzad; Haouzi, Annick; Manoskey, Angela; Stephenson, Edward; El-Banayosy, Aly; Pae, Walter.

In: ASAIO Journal, Vol. 58, No. 4, 01.07.2012, p. 326-329.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices

AU - Soleimani, Behzad

AU - Haouzi, Annick

AU - Manoskey, Angela

AU - Stephenson, Edward

AU - El-Banayosy, Aly

AU - Pae, Walter

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Development of aortic insufficiency (AI) in patients supported with continuous flow left ventricular assist devices (LVAD) can adversely affect pump performance. In this study, we examined the incidence of new AI after LVAD implant at our institution. Pre- and postoperative echocardiograms of 66 patients who received HeartMate II or Heartware LVAD at our institution since June 2008 were reviewed for presence of new AI. Median LVAD support duration was 221 days. New AI developed in 6 patients (9.5%) after a median time of 374.5 days of support. There were no cases of severe or symptomatic AI. There was no significant difference between the AI incidence between HeartMate II and Heartware recipients. For patients who remained on LVAD support at 6 and 12 months, freedom from AI was 100% and 68.4%, respectively. Age, destination therapy status, and duration of support were predictors of new AI after LVAD implant. In conclusion, AI develops frequently during long-term support with continuous flow LVADs, particularly in those supported for longer than 6 months. As we move to the era of long-term LVAD support and destination therapy, further studies with longer follow-ups are required to determine the progression and clinical significance of AI in these patients.

AB - Development of aortic insufficiency (AI) in patients supported with continuous flow left ventricular assist devices (LVAD) can adversely affect pump performance. In this study, we examined the incidence of new AI after LVAD implant at our institution. Pre- and postoperative echocardiograms of 66 patients who received HeartMate II or Heartware LVAD at our institution since June 2008 were reviewed for presence of new AI. Median LVAD support duration was 221 days. New AI developed in 6 patients (9.5%) after a median time of 374.5 days of support. There were no cases of severe or symptomatic AI. There was no significant difference between the AI incidence between HeartMate II and Heartware recipients. For patients who remained on LVAD support at 6 and 12 months, freedom from AI was 100% and 68.4%, respectively. Age, destination therapy status, and duration of support were predictors of new AI after LVAD implant. In conclusion, AI develops frequently during long-term support with continuous flow LVADs, particularly in those supported for longer than 6 months. As we move to the era of long-term LVAD support and destination therapy, further studies with longer follow-ups are required to determine the progression and clinical significance of AI in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84863503715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863503715&partnerID=8YFLogxK

U2 - 10.1097/MAT.0b013e318251cfff

DO - 10.1097/MAT.0b013e318251cfff

M3 - Article

VL - 58

SP - 326

EP - 329

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 4

ER -